Comparative Efficacy of the Novel Diarylquinoline TBAJ-587 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis

Since its conditional approval in 2012, bedaquiline (BDQ) has been a valuable tool for treatment of drug-resistant tuberculosis. More recently, a novel short-course regimen combining BDQ with pretomanid and linezolid won approval to treat highly drug-resistant tuberculosis. Clinical reports of emerg...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jian, Converse, Paul J., Upton, Anna M., Mdluli, Khisimuzi, Fotouhi, Nader, Nuermberger, Eric L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097419/
https://www.ncbi.nlm.nih.gov/pubmed/33526488
http://dx.doi.org/10.1128/AAC.02418-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097419/
https://www.ncbi.nlm.nih.gov/pubmed/33526488
http://dx.doi.org/10.1128/AAC.02418-20

Ejemplares similares